SCHAUMBURG, Ill., March 20, 2024--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for ...

FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ AutoinjectorWESTLAKE ...

BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

ELK GROVE VILLAGE, Ill., Oct. 21, 2024 /PRNewswire/ -- Orsini announced today that it has been chosen by scPharmaceuticals to distribute FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous ...

Hikma has launched furosemide injection, in 20mg/2ml, 40mg/4ml, 100mg/10ml, 500mg/50ml and 1,000mg/100ml presentations. “Hikma is introducing the first FDA approved 50ml and 100ml presentations to the ...

Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- ...

LEXINGTON, Mass., scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial. The trial in patients with heart failure ...

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...